Parkinson’s treatment – Discover Pharma

Welcome to Discover Pharma! Today is : September 29, 2026

Parkinson’s treatment

Biotech & Pharma Business,Central Nervous System,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas
Ariadne Bio launches with Parkinson’s apathy drug candidate
Ariadne Bio has launched with funding from The Michael J [...]

September 18, 2026
Biotech & Pharma Business,Clinical & Regulatory,Digital & Data,Drug Discovery & Development,Pharmaceuticals and therapeutics,Research & Development
Remepy raises $36M to advance Parkinson’s drug into Phase 3
Remepy has raised $36M in a Series A financing round [...]

August 14, 2026
Central Nervous System,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas
AC Immune gets FDA Fast Track for Parkinson’s immunotherapy ACI-7104
AC Immune has received FDA Fast Track designation and IND [...]

August 12, 2026
Central Nervous System,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Research & Development
BioVie reports Phase 2 Parkinson’s trial results for bezisterim
BioVie has reported topline results from a Phase 2 trial [...]

August 7, 2026
Central Nervous System,Clinical & Regulatory,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas
ABLi reports biomarker changes supporting disease-modifying potential of Parkinson’s drug
ABLi Therapeutics has reported coordinated changes across 11 biomarkers linked [...]

August 4, 2026

This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details.

OK